Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

 

 

 

		Fresenius Medical Care AG   POB 61346 Bad Homburg Germany www.freseniusmedicalcare.com
U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 201549

 

February 20, 2024

 

Re:

Notice of Disclosure Filed in Exchange Act Annual Report Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

 

Ladies and Gentlemen:

 

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Fresenius Medical Care AG has made disclosure pursuant to such provisions in its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the U.S. Securities and Exchange Commission on February 20, 2024. Such disclosure begins on page 43 of the Annual Report on Form 20-F and is incorporated by reference herein.

 

Sincerely,

 

By:	/s/ Martin Fischer
Name:	Martin Fischer
Title:	Chief Financial Officer and member of the Management Board

 

Fresenius Medical Care AG, 61346 Bad Homburg, Germany, T [phone], Registered Office and

Commercial Register: Hof (Saale), HRB 6841, VAT-ID No.: DE 811127677, Chair of Supervisory Board: Michael SenManagement Board: Helen Giza (Chair), Martin Fischer, Franklin W. Maddux, Dr. Katarzyna Mazur-Hofsäß, Craig Cordola. Bank Account: Commerzbank AG, Frankfurt/Main, IBAN: DE23 5008 0000 0711 6731 00, SWIFT/BIC: DRESDEFF501

 

 

 

---